{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T19:35:14Z","timestamp":1790969714186,"version":"4.1.0"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T00:00:00Z","timestamp":1691020800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Calcif Tissue Int"],"DOI":"10.1007\/s00223-023-01119-7","type":"journal-article","created":{"date-parts":[[2023,8,3]],"date-time":"2023-08-03T09:02:07Z","timestamp":1691053327000},"page":"469-473","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["The Five-Year Effect of a Single Zoledronate Infusion on Bone Mineral Density Following Denosumab Discontinuation in Women with Postmenopausal Osteoporosis"],"prefix":"10.1007","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9624-6296","authenticated-orcid":false,"given":"Athanasios D.","family":"Anastasilakis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Polyzois","family":"Makras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stergios A.","family":"Polyzos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Socrates E.","family":"Papapoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,3]]},"reference":[{"key":"1119_CR1","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa756","author":"E Tsourdi","year":"2020","unstructured":"Tsourdi E, Zillikens MC, Meier C, Body JJ, Gonzalez Rodriguez E, Anastasilakis AD, Abrahamsen B, McCloskey E, Hofbauer LC, Gua\u00f1abens N, Obermayer-Pietsch B, Ralston SH, Eastell R, Pepe J, Palermo A, Langdahl B (2020) Fracture risk and management of discontinuation of denosumab therapy: a systematic review and position statement by ECTS. J Clin Endocrinol Metab. https:\/\/doi.org\/10.1210\/clinem\/dgaa756","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"1119_CR2","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1002\/jbmr.3853","volume":"34","author":"AD Anastasilakis","year":"2019","unstructured":"Anastasilakis AD, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Makras P (2019) Zoledronate for the prevention of bone loss in women discontinuing Denosumab treatment. A prospective 2-year clinical trial. J Bone Miner Res 34(12):2220\u20132228","journal-title":"J Bone Miner Res"},{"key":"1119_CR3","doi-asserted-by":"publisher","first-page":"115478","DOI":"10.1016\/j.bone.2020.115478","volume":"138","author":"P Makras","year":"2020","unstructured":"Makras P, Papapoulos SE, Polyzos SA, Appelman-Dijkstra NM, Anastasilakis AD (2020) The three-year effect of a single zoledronate infusion on bone mineral density and bone turnover markers following denosumab discontinuation in women with postmenopausal osteoporosis. Bone 138:115478","journal-title":"Bone"},{"issue":"7","key":"1119_CR4","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1002\/jbmr.3962","volume":"35","author":"J Everts-Graber","year":"2020","unstructured":"Everts-Graber J, Reichenbach S, Ziswiler HR, Studer U, Lehmann T (2020) A single infusion of zoledronate in postmenopausal women following denosumab discontinuation results in partial conservation of bone mass gains. J Bone Miner Res 35(7):1207\u20131215","journal-title":"J Bone Miner Res"},{"issue":"6","key":"1119_CR5","doi-asserted-by":"publisher","first-page":"1389","DOI":"10.1016\/j.bone.2012.03.016","volume":"50","author":"A Grey","year":"2012","unstructured":"Grey A, Bolland MJ, Horne A, Wattie D, House M, Gamble G, Reid IR (2012) Five years of anti-resorptive activity after a single dose of zoledronate\u2013results from a randomized double-blind placebo-controlled trial. Bone 50(6):1389\u20131393","journal-title":"Bone"},{"issue":"1","key":"1119_CR6","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1007\/s12325-021-01936-y","volume":"39","author":"DL Kendler","year":"2022","unstructured":"Kendler DL, Cosman F, Stad RK, Ferrari S (2022) Denosumab in the treatment of osteoporosis: 10 years later: a narrative review. Adv Ther 39(1):58\u201374","journal-title":"Adv Ther"},{"issue":"6","key":"1119_CR7","doi-asserted-by":"publisher","first-page":"1033","DOI":"10.1002\/jbmr.3722","volume":"34","author":"S Ferrari","year":"2019","unstructured":"Ferrari S, Libanati C, Lin CJF, Brown JP, Cosman F, Czerwinski E, de Gregomicronrio LH, Malouf-Sierra J, Reginster JY, Wang A, Wagman RB, Lewiecki EM (2019) Relationship between bone mineral density t-score and Nonvertebral fracture risk over 10 years of Denosumab treatment. J Bone Miner Res 34(6):1033\u20131040","journal-title":"J Bone Miner Res"},{"issue":"11","key":"1119_CR8","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1002\/jbmr.4705","volume":"37","author":"F Cosman","year":"2022","unstructured":"Cosman F, Huang S, McDermott M, Cummings SR (2022) Multiple vertebral fractures after Denosumab discontinuation: freedom and freedom extension trials additional post hoc analyses. J Bone Miner Res 37(11):2112\u20132120","journal-title":"J Bone Miner Res"},{"issue":"10","key":"1119_CR9","doi-asserted-by":"publisher","first-page":"1858","DOI":"10.1002\/jbmr.4098","volume":"35","author":"AS S\u00f8lling","year":"2020","unstructured":"S\u00f8lling AS, Harsl\u00f8f T, Langdahl B (2020) Treatment with Zoledronate subsequent to Denosumab in osteoporosis: a randomized trial. J Bone Miner Res 35(10):1858\u20131870","journal-title":"J Bone Miner Res"},{"issue":"10","key":"1119_CR10","doi-asserted-by":"publisher","first-page":"e4155","DOI":"10.1210\/clinem\/dgab321","volume":"106","author":"P Makras","year":"2021","unstructured":"Makras P, Appelman-Dijkstra NM, Papapoulos SE, van Wissen S, Winter EM, Polyzos SA, Yavropoulou MP, Anastasilakis AD (2021) The duration of Denosumab treatment and the efficacy of Zoledronate to preserve bone mineral density after its discontinuation. J Clin Endocrinol Metab 106(10):e4155\u2013e4162","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"1119_CR11","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1038\/s41584-023-00935-3","volume":"19","author":"S Ferrari","year":"2023","unstructured":"Ferrari S, Langdahl B (2023) Mechanisms underlying the long-term and withdrawal effects of denosumab therapy on bone. Nat Rev Rheumatol 19(5):307\u2013317","journal-title":"Nat Rev Rheumatol"},{"issue":"9","key":"1119_CR12","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.1002\/jbmr.4335","volume":"36","author":"P Burckhardt","year":"2021","unstructured":"Burckhardt P, Faouzi M, Buclin T, Lamy O (2021) The Swiss Denosumab study, fractures after Denosumab discontinuation: a retrospective study of 797 cases. J Bone Miner Res 36(9):1717\u20131728","journal-title":"J Bone Miner Res"},{"key":"1119_CR13","doi-asserted-by":"publisher","first-page":"115830","DOI":"10.1016\/j.bone.2020.115830","volume":"144","author":"J Everts-Graber","year":"2021","unstructured":"Everts-Graber J, Reichenbach S, Gahl B, Ziswiler HR, Studer U, Lehmann T (2021) Risk factors for vertebral fractures and bone loss after denosumab discontinuation: a real-world observational study. Bone 144:115830","journal-title":"Bone"}],"container-title":["Calcified Tissue International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-023-01119-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00223-023-01119-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00223-023-01119-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,22]],"date-time":"2023-09-22T18:02:37Z","timestamp":1695405757000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00223-023-01119-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,3]]},"references-count":13,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["1119"],"URL":"https:\/\/doi.org\/10.1007\/s00223-023-01119-7","relation":{},"ISSN":["1432-0827"],"issn-type":[{"value":"1432-0827","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,3]]},"assertion":[{"value":"14 May 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Athanasios D. Anastasilakis reports lecture fees from Amgen, Bianex, Eli-Lilly, Galenica, ITF, Unifarma, and UCB; Polyzois Makras reports fees for lectures\/advisory boards and research grants from Amgen and fees for lectures\/advisory boards from UCB, Elpen, and Galenica; Stergios A. Polyzos has nothing to declare; Socrates E. Papapoulos reports consulting\/speaking fees from Amgen, Entera Bio, Qualix Dot, Radius Health, and UCB.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in the study were in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. The study\u00a0was approved by the local ethics committee.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}},{"value":"No animals were involved in the study. Informed consent was obtained from all individual participants included in the study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights and Informed Consent"}}]}}